Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

223.43
+4.412.01%
Post-market: 222.03-1.4000-0.63%19:56 EST
Volume:6.07M
Turnover:1.35B
Market Cap:394.89B
PE:94.67
High:225.82
Open:218.75
Low:218.50
Close:219.02
52wk High:244.81
52wk Low:164.39
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.66
T/O Rate:0.34%
Dividend:6.65
Dividend Rate:2.98%
EPS(TTM):2.36
EPS(LYR):2.36
ROE:1106.67%
ROA:9.59%
PB:-149.47
PE(LYR):94.67

Loading ...

AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Yesterday

AbbVie (ABBV) Receives a Buy from Guggenheim

TIPRANKS
·
Feb 06

CORRECTED-CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)

Reuters
·
Feb 06

Abbvie Inc. : Morgan Stanley Raises Target Price to $270.00 From $269.00

THOMSON REUTERS
·
Feb 05

AbbVie Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Feb 05

AbbVie Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Feb 05

Morgan Stanley Lifts Price Target on AbbVie to $270 From $269, Keeps Overweight Rating

MT Newswires Live
·
Feb 05

BUZZ-Street View: AbbVie's strong drug pipeline sets it up well for long‑term growth

Reuters
·
Feb 05

U.S. RESEARCH ROUNDUP-Alphabet, Corteva, Varonis Systems

Reuters
·
Feb 05

AbbVie Earnings Call: New Growth Engines Take Lead

TIPRANKS
·
Feb 05

Health Care Up After Eli Lilly Earnings -- Health Care Roundup

Dow Jones
·
Feb 05

AbbVie Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Feb 05

Evercore ISI Adjusts AbbVie Price Target to $228 From $232, Maintains Outperform Rating

MT Newswires Live
·
Feb 05

AbbVie price target lowered to $228 from $232 at Evercore ISI

TIPRANKS
·
Feb 05

Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy

TIPRANKS
·
Feb 05

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

Benzinga
·
Feb 05

Abbvie Exec Says Peak Sales for Parkinson's and Migraine Franchises Could Exceed $5 Billion

THOMSON REUTERS
·
Feb 04

Abbvie Exec Says Continue to Expect Low Single Digit Pricing Headwinds for Both Skyrizi and Rinvoq in 2026 and Over the Next Few Years as Well

THOMSON REUTERS
·
Feb 04

Abbvie Exec Says Have Plenty of Firepower to Pursue Both Early and Late Stage M&a Opportunities - Conf Call

THOMSON REUTERS
·
Feb 04

Abbvie Exec Says Potential Deals Not Limited to Early Stage, and Focused on Core Areas, Immunology, Neuroscience, Oncology and Building Out Obesity

THOMSON REUTERS
·
Feb 04